嚢胞性線維症(CF)治療薬のパイプライン分析 2018年

◆英語タイトル:Global Cystic Fibrosis Pipeline Analysis -2018
◆商品コード:EFF804010
◆発行会社(リサーチ会社):Effectual Services
◆発行日:2018年3月19日
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD3,499 ⇒換算¥395,387見積依頼/購入/質問フォーム
Global Site LicenseUSD5,499 ⇒換算¥621,387見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はEffectual Services社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Effectual Services社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Cystic fibrosis is a rare genetic disorder caused by the mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene located on chromosome 7. It largely affects the lungs and digestive system, and causes the secretions to become thick and sticky. The individuals with cystic fibrosis develop lung disease, resulting from a cycle of mucus retention, infection and inflammation, and pancreatic dysfunction results in calorie malabsorption. The sweat glands and reproductive organs are also get affected. The sequence of the CFTR gene was identified in 1989 and it encodes a 1480 amino acid protein. There are approximately 250 known disease-causing mutations that intervene various stages of CFTR synthesis and function. Every year approximately 70,000 children and young adults are affected with CF across the world.
The current treatment of CF comprises of symptomatic therapy mainly. The objective of the treatment includes as follows:
• prevent and control lung infections
• loosen and eliminate thick, sticky mucus from the lungs
• prevent or treat blockages in the intestines
• maintain good nutrition
• avert dehydration
• early identification and treatment of the comorbidities associated with the disease

The cystic fibrosis pipeline is comprised of diverse sets of molecules with a majority of products in early-stage development. In total 124 molecules are in development either alone or in combination with other molecules. Majority of those are in the pre-clinical development stage followed by Phase II and Phase I. Earlier the CF treatment was largely focused on the downstream effects of CFTR dysfunction (mucus retention, infection, and inflammation of the airways) and there have been many advances on those problems. However, new therapies such as CFTR modulators are able to address the underlying abnormality rather than its downstream effects. The efficacy of these treatments has been established recently. At present there are just three FDA approved molecules are commercially available in the market that targets the specific mutation types.

Majority of the companies are focusing on the modulators of CFTR gene followed by anti-infectives. The cystic fibrosis drug market is very competitive; many small players are working in the same. Vertex Pharmaceuticals, Galapagos, Flatley Discovery Lab, Ockham Biotech, Proteostasis Therapeutics and Druggability Technologies Holdings are leading the space.

【レポートの目次】

Executive Summary
1. Cystic Fibrosis: Disease Overview
I. Clinical Manifestations and Complications of Cystic Fibrosis
II. Etiology and Genetics of Cystic Fibrosis
a. Basics of Genetics and the CFTR Gene
b. Role of CFTR Protein in Ion Transport
c. The CFTR Gene Mutations
d. Classification of Mutations of CFTR Gene
III. Diagnosis of Cystic Fibrosis
IV. Treatment Methodology of Cystic Fibrosis
a. Treatment of Lung Complications
b. Treatment for Advanced Lung Disease
c. Treatment for Digestive Problems
2. Pipeline Analysis of Cystic Fibrosis
I. Cystic Fibrosis Drug Pipeline by Stage of Development
II. Cystic Fibrosis Drug Pipeline by Therapeutic Class
a. Anti-Infective
b. Anti-Inflammatory
c. CFTR Modulator
d. Mucociliary Clearance
e. Nutritional
f. Miscellaneous
III. Cystic Fibrosis Drug Pipeline by Molecule Type
IV. Cystic Fibrosis Drug Pipeline by Route of Administration
V. Cystic Fibrosis Drug Pipeline by Therapy Type
VI. Cystic Fibrosis Drug Pipeline by Company

Fig 1.1 Clinical Manifestations and Complications of Cystic Fibrosis
Fig 1.2 Mode of Inheritance of Cystic Fibrosis
Fig 2.1 Cystic Fibrosis Drug pipeline by Stage of Development
Fig 2.2 Cystic Fibrosis Drug Pipeline by Therapeutic Class
Fig 2.3 Cystic Fibrosis Drug Pipeline by Anti-Infective Class
Fig 2.4 Cystic Fibrosis Drug Pipeline by Anti-Inflammatory Class
Fig 2.5 Cystic Fibrosis Drug Pipeline by CFTR Modulator Class
Fig 2.6 Cystic Fibrosis Drug Pipeline by Mucociliary Clearance Class
Fig 2.7 Cystic Fibrosis Miscellaneous Drug Pipeline
Fig 2.8 Cystic Fibrosis Drug Pipeline by Molecule Type
Fig 2.9 Cystic Fibrosis Drug Pipeline by Route of Administration
Fig 2.10 Cystic Fibrosis Drug Pipeline by Therapy Type
Fig 2.11 Cystic Fibrosis Drug Pipeline by Company


Table 1.1 Classification of CFTR Mutations
Table 2.1 Cystic Fibrosis Drug Pipeline by Stage of Development
Table 2.2 Cystic Fibrosis Drug Pipeline by Anti-Infective Class
Table 2.3 Expanded Label Cystic Fibrosis Drug Pipeline by Anti-Infective Class
Table 2.4 Cystic Fibrosis Drug Pipeline by Anti-Inflammatory Class
Table 2.5 Cystic Fibrosis Drug Pipeline by CFTR Modulator Class
Table 2.6 Expanded Label Cystic Fibrosis Drug Pipeline by CFTR Modulator Class
Table 2.7 Cystic Fibrosis Drug Pipeline by Mucociliary Clearance Class
Table 2.8 Cystic Fibrosis Drug Pipeline by Mucociliary Clearance Class for Different Geographies
Table 2.9 Cystic Fibrosis Drug Pipeline by Nutritional Class
Table 2.10 Cystic Fibrosis Miscellaneous Drug Pipeline
Table 2.11 Cystic Fibrosis Drug Pipeline by Company


【レポートのキーワード】

嚢胞性線維症(CF)治療薬

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[嚢胞性線維症(CF)治療薬のパイプライン分析 2018年]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆